MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3802/jgo.2024.35.e115

Медицинская библиотека · Journal of gynecologic oncology · 2024

Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study.

Itamochi Hiroaki, Takeshima Nobuhiro, Hamanishi Junzo, Hasegawa Kosei, Matsuura Motoki, Miura Kiyonori, Nagao Shoji, Nakai Hidekatsu, Tanaka Naotake, Tokunaga Hideki, Nishio Shin, Watari Hidemichi, Yokoyama Yoshihito, Kase Yoichi, Sumino Shuuji, Kato Ai, Suri Ajit, Yasuoka Toshiaki, Takehara Kazuhiro

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVE

This study evaluated the long-term safety and efficacy of niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer.

METHODS

This was a follow-up analysis of a phase 2, multicenter, open-label, single-arm study in Japanese women with platinum-sensitive, relapsed ovarian cancer. Participants received niraparib (starting dose 300 mg) once daily in continuous 28-day cycles. The primary endpoint was the incidence of Grade 3 or 4 thrombocytopenia-related events (defined as the overall incidence of the MedDRA Preferred Terms "thrombocytopenia" and "platelet count decreased") occurring in the 30 days after initial administration of niraparib, and secondary endpoints included evaluation of treatment-emergent adverse events and progression-free survival.

RESULTS

Nineteen patients (median age, 62 years; median body weight, 53.9 kg) were enrolled. As previously reported, the incidence of Grade 3 or 4 thrombocytopenia-related events during the first 30 days of treatment was 31.6%. At data cutoff, median (range) treatment exposure was 504.0 (56-1,054) days and mean ± standard deviation dose intensity was 154.4±77.5 mg/day. The most common treatment-emergent adverse events were nausea (n=14, 73.7%), decreased platelet count (n=12, 63.2%), decreased neutrophil count (n=11, 57.9%), anemia, vomiting, and decreased appetite (all n=9, 47.4%). One patient was diagnosed with treatment-related leukemia, which resulted in death. Median (95% confidence interval) progression-free survival was 18.0 (5.6-26.7) months.

CONCLUSION

Overall, the safety profile of niraparib was considered manageable in this study population of Japanese patients with platinum-sensitive, relapsed ovarian cancer and was consistent with that observed in studies of non-Japanese patients.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03759587.

Для цитирования: Itamochi Hiroaki, Takeshima Nobuhiro, Hamanishi Junzo, Hasegawa Kosei, Matsuura Motoki, Miura Kiyonori, Nagao Shoji, Nakai Hidekatsu, Tanaka Naotake, Tokunaga Hideki, Nishio Shin, Watari Hidemichi, Yokoyama Yoshihito, Kase Yoichi, Sumino Shuuji, Kato Ai, Suri Ajit, Yasuoka Toshiaki, Takehara Kazuhiro. Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study.. Journal of gynecologic oncology. 2024. DOI: 10.3802/jgo.2024.35.e115.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.